rivastigmine.txt

CLINICAL USE

Mild-moderate dementia in Alzheimer’s diseaseIdiopathic Parkinson’s disease

DOSE IN NORMAL RENAL FUNCTION

3–6 mg twice daily (initially 1.5 mg twice daily)

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :250.3 (400.4 as hydrogen tartrate)

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :40

%Excreted unchanged in urine &nbsp &nbsp : 0 (>90 as pharmacologically inactive metabolites)

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :1.8–2.7

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :1/–

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Start at a low dose and gradually increase

10 to 20 &nbsp &nbsp : Start at a low dose and gradually increase

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Start at a low dose and gradually increase

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Likely dialysability. Dose as in GFR <10 mL/min

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Likely dialysability. Dose as in GFR <10 mL/min

HDF/high flux &nbsp :Likely dialysability. Dose as in GFR <10 mL/min

CAV/VVHD &nbsp &nbsp &nbsp:Likely dialysability. Dose as in GFR=10-20 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsMuscle relaxants: enhances effect of suxamethonium; antagonises effect of non-depolarising muscle relaxants

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Administer with food. Swallow whole .

Tags: post-by-auto-php